Direct-to-Patient Logistics: A DCT Compliance Guide

What Direct-to-Patient Logistics Actually Covers

Direct-to-patient logistics moves investigational medicinal product from a depot or pharmacy to a trial participant's home. Direct-from-patient logistics moves that participant's biological samples back to a central laboratory. Most decentralized trials run both directions at once.

That two-way flow is what separates DTP from ordinary clinical supply. A site-to-site shipment ends at a controlled facility with trained staff. A DTP shipment ends at a front door, and the return leg starts there too.

Hybrid designs sit in between. Participants visit a site for procedures that need supervision and receive product at home between visits. The supply chain has to support both patterns in the same study.

The Regulatory Picture Has Changed

Decentralized trials are no longer an improvised arrangement. FDA issued its final guidance, Conducting Clinical Trials With Decentralized Elements, in September 2024, and it is now in effect (U.S. Food and Drug Administration).

The guidance treats decentralized activity as a design choice that must be justified for the investigational product and the trial population, rather than a default. It also addresses access, noting that participants who do not own a protocol-specified digital health technology should not be excluded for that reason (U.S. Food and Drug Administration).

Alongside it, the modernized Good Clinical Practice standard applies. ICH E6(R3) took effect in the European Union on 23 July 2025 and was adopted by FDA on 9 September 2025 (European Medicines Agency).

ICH E6(R3) Annex 2 and the January 2027 Deadline

The development that matters most for supply chains is Annex 2. It provides GCP considerations for non-traditional designs, including decentralized and pragmatic trials and trials using real world data sources.

ICH adopted Annex 2 at Step 4 on 3 June 2026, and CHMP adopted it on 25 June 2026. It comes into effect on 15 January 2027 (International Council for Harmonisation). FDA has not published a US implementation date, but sponsors running trials in the EU or UK are already in scope.

The practical message for logistics is that a decentralized supply chain must be fit for its intended purpose and risk-proportionate, and you must be able to evidence that. Sponsors should be reviewing DTP vendor qualification, temperature evidence, and documentation now rather than in late 2026.

Cold Chain to the Front Door

Many investigational products require controlled temperature from depot to doorstep. Biologics, cell and gene therapies, and vaccines lose therapeutic value after an excursion, and a home has no validated storage to fall back on.

That constraint changes the packaging brief. The shipper must hold its range through the full transit window plus a realistic buffer for a missed handoff, not just the planned duration. Validated, qualified packaging is the baseline, as covered in our guide to packaging validation.

Delivery timing matters as much as the packaging. Product should arrive when the participant or caregiver is present to receive it and can store it correctly. A coordinated delivery window is a compliance control, not a convenience.

Specialty cold chain services combine qualified packaging with monitored transport so the temperature record follows the shipment to the door. That record is the evidence an inspector will ask for.

Kits, Devices, and Ancillary Supplies

DTP programs move far more than the investigational product. Participants also receive sample collection kits, diagnostic devices, wearables, return packaging, and instructions, and each item needs to arrive before study activities begin.

Kit design carries real risk. A kit that is hard to use, or that lacks correct return packaging, produces unusable samples and lost data points. Our guide to clinical trial kit building covers assembly and labeling requirements in detail.

Device accountability adds a tracking layer. Sponsors must know which participant holds which device, and be able to recover equipment at the end of participation.

Direct-from-Patient Sample Returns

The return leg deserves the same rigor as the outbound leg, and it usually gets less. Samples collected at home travel to a central laboratory, and their analytical validity depends on how quickly and how coldly they travel.

Direct-from-patient services schedule collection around the participant rather than the courier, which is what makes the return leg reliable. Some assays require same-day delivery to the lab, so service level has to match the protocol.

Ambient, refrigerated, and frozen samples each need their own packaging and monitoring. Building the return conditions into the protocol, rather than solving them later, prevents avoidable sample loss.

Chain of Custody, Blinding, and Privacy

Investigational product distribution follows Good Distribution Practice whether it lands at a hospital or a house. A home address does not lower the standard.

Chain of custody documentation has to record every handoff from depot release to participant receipt. Electronic proof of delivery, timestamps, and signatures build the audit trail that supports inspection.

Blinding and privacy create requirements unique to DTP. Packaging and labels must not unblind the study, and they must not disclose a participant's condition to anyone who handles the parcel. Shipping data is participant data and belongs under the same protection as the rest of the trial record.

Country rules also differ. Some jurisdictions restrict home delivery of certain product categories outright, so global protocols need those limits mapped during design rather than discovered at launch.

Building a DCT Supply Chain That Scales

A DTP program that works for one site rarely survives expansion without structure. Regional depots shorten transit times, which directly reduces excursion risk and shipping cost.

Standardized processes keep execution consistent across countries, and they make evidence consistent too. Under a risk-proportionate GCP standard, uniform documentation is easier to defend than bespoke handling per site.

Flexibility matters as enrollment shifts. Inventory positioning and routing should adapt as participants join in new regions, without renegotiating the whole model. The same discipline that supports end-to-end cold chain for clinical trials applies here at a finer grain.

How Mercury Supports Direct-to-Patient Programs

Mercury provides clinical trial logistics built for decentralized and hybrid designs, including direct-to-patient and direct-from-patient service in both directions.

We coordinate delivery windows with participants, maintain temperature monitoring across the journey, and document chain of custody at each handoff so your quality team has the evidence it needs. Our dedicated teams track shipments in motion and act on exceptions before they become protocol deviations.

We also work with sponsors on country-specific restrictions during protocol design, so distribution constraints surface early instead of at first shipment.

To prepare your direct-to-patient supply chain ahead of the January 2027 Annex 2 deadline, contact Mercury today.